Background: Biofilms are characteristic of some chronic or recurrent infections and this mode of growth tends to reduce treatment efficacy. Clostridium difficile infection (CDI) is associated with a high rate of recurrent symptomatic disease. The presence and behaviour of C. difficile within intestinal biofilms remains largely unexplored, but may factor in recurrent infection.
Introduction
Clostridium difficile infection (CDI) is associated with significant morbidity, mortality and financial burden worldwide. 1 For many years, metronidazole and vancomycin have been the only first-line treatment options for CDI; notably, both are associated with recurrence in 20% of patients. 2 Fidaxomicin is a new therapeutic option for CDI that is associated with significantly lower recurrence rates for most but not all C. difficile types. 3 It is known that antibiotic treatment of CDI does not achieve microbiological cure in some patients even when symptoms do cease. 4, 5 Persistence of C. difficile spores is believed to be a key explanation for the high rates of recurrent CDI. The human gastrointestinal tract harbours a complex microbial community, existing both as planktonic, free-floating bacteria in the gut lumen and mucosal, sessile microorganisms present in biofilm structures. 6 -8 The biofilm mode of growth is ubiquitous in nature and often considered the natural state for bacterial growth. Sessile bacteria often possess distinct characteristics from their planktonic counterparts, such as displaying a reduced susceptibility to antimicrobial agents. 9 Intestinal biofilm structures remain largely unexplored, due in part to the physical inaccessibility of healthy colonic mucosa. However, studies of colonic biopsies have identified distinct differences between mucosal-and faeces-associated bacterial populations. 6 C. difficile is known to adhere to mucus and intestinal cell lines, with the apparent formation of cellular aggregates on the epithelia of diseased mice. 10 -12 The adherence of pure C. difficile cultures to abiotic surfaces has recently been characterized. 13 -15 However, these simple model systems cannot accurately simulate the complex bacterial communities and environmental conditions of the human colon. Here, we report the use of an in vitro model of the human gastrointestinal tract, which has been validated to facilitate the formation and analysis of complex, mixed-species biofilms. 16 This model system has been utilized to investigate both planktonic and biofilm-associated communities of C. difficile and the indigenous gut microbiota, allowing the evaluation of the possible roles of these respective microbial communities in primary and recurrent CDI. Furthermore, the activity of clindamycin and vancomycin against these two distinct modes of growth has been investigated.
Methods

C. difficile strains
The C. difficile strain evaluated in this study was PCR ribotype 027 (NAP1/BI), isolated during an outbreak of CDI at Maine Medical Centre (Portland, MA, USA) in 2005, and was supplied courtesy of Dr Robert Owens (Maine Medical Centre).
Triple-stage chemostat biofilm human gut model
A validated chemostat gut model of simulated CDI has been utilized by our group to investigate the interaction between antimicrobial agents, planktonic indigenous gut microbiota and C. difficile populations. 17 -20 More recently, we have described the adaptation and validation of this original model system to facilitate the independent formation and analysis of mature, mixed-species biofilm formation. 16 Briefly, the gut model comprises three pH-maintained (pH 5.5+0.2, vessel 1; pH 6.2+0.2, vessel 2; and pH 6.8+0.2, vessel 3) fermentation vessels inoculated with a faecal emulsion [ 10% (w/v) in pre-reduced PBS] prepared from C. difficilenegative faeces of three healthy elderly (≥60 years) volunteers with no history of antimicrobial therapy for ≥3 months prior to the study. Vessels were connected in a weir cascade formation, maintained within an anaerobic atmosphere and top-fed by a complex growth medium at a controlled rate (D¼0.015 h
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). Constituents and preparation of growth medium for the gut model were as described previously. 19 Vessel 3 comprised a design that incorporated 18 glass rods to facilitate biofilm formation. Each rod could be removed and analysed independently whilst maintaining the integrity of the system.
Experimental design
Following inoculation of faecal emulsion into all three vessels of the model, the media pump was started and the system was left without interventions for 20 days to allow bacterial populations to equilibrate (Figure 1 , period A). A single inoculum of C. difficile PCR ribotype 027 spores ( 10 7 cfu) was inoculated into vessel 1 of the model on day 21 (period B). The system was left without further intervention until rods 1 -3 were sampled on day 27 (timepoint Z). On day 28, a further inoculum of C. difficile 027 spores ( 10 7 cfu) was instilled into vessel 1 to re-establish C. difficile populations, along with a dosing regimen of clindamycin (33.9 mg/L, four times daily, 7 days-period C). Rods 4 -6 and 7 -9 were sampled on days 35 (timepoint Y) and 41 (timepoint X), respectively. Once high-level cytotoxin titre [≥4 relative units (RU)] was observed within the planktonic fluid (period D), instillation of vancomycin commenced on day 43 (125 mg/L, four times daily, 7 days-period E). The model was left without intervention for a further 24 days (period F). A further three rods were sampled at each timepoint; W, V and U on days 52, 59 and 73, respectively. Planktonic indigenous gut microbiota (periods A -F, vessels 2 and 3), C. difficile total viable counts, spores and cytotoxin (periods B -F, vessels 1 -3) and antimicrobial activity (periods C-F, vessels 1-3) were monitored daily (every 2 days, period A only). Sessile indigenous gut microbiota (timepoints Z -U), C. difficile total viable counts, spores and cytotoxin (timepoints Z -U) and antimicrobial activity (timepoints Y -U) were monitored during the experiment.
Enumeration of gut microbiota populations, C. difficile total viable counts, spores and cytotoxin titre
The planktonic and sessile bacterial groups and culture media used in this study are detailed in Table 1 . Briefly, planktonic culture fluid was serially diluted in pre-reduced peptone water to 10 27 and 20 mL of appropriate dilution inoculated onto quarter plates of each solid culture medium in Crowther et al.
triplicate. Inoculated plates were incubated anaerobically (obligate anaerobes) or aerobically (facultative anaerobes) at 378C for 48 h. Bacterial colonies were identified, based on colony morphology, Gram stain reaction and microscopic morphology, and enumerated. Indigenous gut microbiota populations from vessel 1 of the gut models were not determined because the proximal colon is of less physiological relevance in CDI than the distal colon. Biofilm-associated bacterial populations were enumerated following removal of rods from vessel 3 of the model. Rods were transferred into 5 mL of pre-reduced saline, thoroughly vortexed for 2 min and the rod discarded. Total resuspended biofilm was then centrifuged at 4000 g for 10 min and the pellet resuspended in 2 mL of pre-reduced saline.
Planktonic and biofilm aliquots (500 mL) were centrifuged and stored at 48C for cytotoxin assay as described previously 21 and 2208C for quantification of antimicrobial activity. Planktonic and biofilm aliquots (1 mL) were centrifuged (16 000 g, 10 min) in a pre-weighed Eppendorf and the pellet weight determined. Gut microbiota and C. difficile populations were enumerated as described for planktonic populations and units were reported as log 10 cfu/g of culture pellet weight.
Detection and quantification of antimicrobial activity
One millilitre planktonic (all vessels) and 500 mL sessile (all rods) samples were centrifuged (15 min, 16000 g) and the supernatants sterilized by filtration through 0.22 mm syringe filters and stored at 2208C. The concentration of active clindamycin and vancomycin was determined by separate in-house, large-plate bioassays. Briefly, 1 mL of indicator organism ( 10 8 cfu/mL) was added to 100 mL of molten (508C) agar (Table 2) . Inoculated agars were mixed by inversion, poured into 245×245 mm agar plates and allowed to set. Inoculated agars were dried (378C) for 10 min and 25 wells (each 9 mm in diameter) removed from the agar using a cork borer. Twenty microlitres of target agent calibrator (doubling dilution calibration series) or each filter-sterilized sample from the gut model was randomly assigned to bioassay wells in triplicate. Bioassay plates remained at ambient temperature for 4 h prior to overnight aerobic incubation at 378C. Zone diameters were measured using callipers accurate to 0.1 mm. Calibration lines were plotted from squared zone diameters and unknown concentrations from culture supernatants determined. Coefficient-of-variation values were typically 10% and R 2 values for calibration lines were all ≥0.97. Quantification of biofilm-associated antimicrobial activity was determined using the assumption that 1 g of biofilm was equal to 1 mL of planktonic culture fluid; therefore, the results obtained utilizing this method should be interpreted with caution.
Results
Planktonic indigenous gut microbiota populations
Vessel 3 of the gut model represents the distal colon and is therefore of most physiological relevance to the study of CDI; hence, results from this vessel only will be detailed here. The majority of indigenous gut microbiota bacterial groups reached steady-state midway through period A, with the exception of Enterococcus spp., which continued a gradual increase until the end of period B (Figure 2a Comparison of planktonic and biofilm communities within a gut model and b). The instillation of C. difficile spores on day 21 (period B) did not appear to affect gut microbiota populations, with levels remaining steady. Clindamycin instillation (Figure 2a and b, period C) elicited a precipitous decline in Bifidobacterium spp. ( 8 log 10 cfu/mL decline), with populations declining to below the limit of detection (LOD) 4 days after instillation commenced. A less marked decline was evident in Bacteroides fragilis group ( 1 log 10 cfu/mL), Clostridium spp. ( 2 log 10 cfu/mL) and Lactobacillus spp.
( 1.5 log 10 cfu/mL). Vancomycin instillation (Figure 2a and b, period E) commenced 8 days after clindamycin cessation and resulted in profound decreases in viable counts of B. fragilis group ( 6-6.5 log 10 cfu/mL) and Bifidobacterium spp. ( 6 log 10 cfu/mL). Smaller declines in Enterococcus spp., lactose-fermenting Enterobacteriaceae and Clostridium spp. were evident, although Lactobacillus spp. populations increased ( 1-1.5 log 10 cfu/mL). Most bacterial groups recovered to or exceeded pre-vancomycin levels 9 days after dosing cessation, except Bifidobacterium spp., which recovered after 18-21 days (period F). Crowther et al.
Sessile indigenous gut microbiota populations
Rod-associated bacterial populations were monitored at six different timepoints (Z-U, Figure 3a and b). Bacterial group populations on each rod at timepoint Z displayed little variation (Figure 3a and b). Lactose-fermenting Enterobacteriaceae (mean 9.2 log 10 cfu/g) dominated sessile bacterial populations, with B. fragilis group and Lactobacillus spp. (mean 8.1 and 8.2 log 10 cfu/g, respectively) the least populous groups.
Clindamycin instillation commenced 8 days prior to timepoint Y. Sessile Bifidobacterium spp. populations were diminished ( 4.5 log 10 cfu/g), but maintained an average population of 3.9 log 10 cfu/g. More modest decreases in sessile Lactobacillus spp. ( 1.5 log 10 cfu/g), Clostridium spp. ( 1 log 10 cfu/g), Enterococcus spp. ( 1 log 10 cfu/g) and B. fragilis group ( 1 log 10 cfu/g) were also seen. Sessile populations at timepoint X remained at similar levels to those at timepoint Y, although Bifidobacterium spp. increased by 1.5 log 10 cfu/g. Vancomycin instillation commenced 10 days before biofilm sampling point W, resulting in a marked decline in sessile B. fragilis group and Bifidobacterium spp. to below the LOD and lactose-fermenting Enterobacteriaceae by 2 log 10 cfu/g, whilst Lactobacillus spp. increased by 2.5 log 10 cfu/g. Sessile Bifidobacterium spp. populations remained below the LOD Planktonic C. difficile populations C. difficile populations comprised primarily of spores during the internal control period (period B, Figure 4) , declining from 5.2 to 4 log 10 cfu/mL as the vessel contents were diluted. Cytotoxin was not detected (period B). A second inoculum of C. difficile spores concurrent with the start of clindamycin dosing (period C) was instilled on day 28. C. difficile populations initially existed primarily as spores until a marked increase in total viable counts relative to spore counts was observed 5 days after clindamycin instillation cessation. Total viable counts peaked at 6.5 log 10 cfu/mL 1 day before the cytotoxin titre peaked at 4 RU. Vancomycin instillation (period E) elicited a rapid decline in total viable counts ( 2 log 10 cfu/mL), with only spores remaining after 2 days. Cytotoxin decreased to below the LOD 5 days after the start of vancomycin instillation. Total viable counts increased relative to spores 18 days after vancomycin cessation. A subsequent increase in cytotoxin was observed, reaching peak titres of 4 RU by the end of the experiment.
Sessile C. difficile populations
Rod-associated C. difficile populations remained primarily as spores for the duration of the experiment (Figure 5) . At timepoint Z, C. difficile rod-associated population levels were consistent across the three rods and existed primarily as spores ( 5.8 log 10 cfu/g). Instillation of a second inoculum of C. difficile spores did not greatly affect sessile C. difficile populations, although variation in populations [as measured by standard error (SE)] between different rods increased modestly (SE timepoint Z,+0.05 -0.09 log 10 cfu/g; SE timepoint Y,+0.36-0.37 log 10 cfu/g). Cytotoxin was not detected within biofilm structures at timepoints Z and Y. During simulated planktonic CDI, sessile C. difficile (timepoint X) continued to maintain a stable population, comprised primarily of spores ( 5.5 log 10 cfu/g). Cytotoxin was detected at low levels (1 RU) within one of the three rods. During timepoints W and V, C. difficile populations remained as spores at 5.5 log 10 cfu/g with no toxin detected. During recurrent planktonic infection (timepoint U), sessile C. difficile populations remained in spore form with only a modest decline ( 0.5 log 10 cfu/g). Cytotoxin was detected in one of the three rods at low levels (2 RU).
Antimicrobial activity
Clindamycin was detected within the planktonic phase of all three vessels of the gut model, peaking at a concentration of 64.9, 50.7 and 50.8 mg/L in vessels 1, 2 (data not shown) and 3 (Figure 4 ), respectively. Clindamycin activity in the planktonic phase continued to be detected 1, 2 and 3 days after dosing cessation in vessels 1, 2 and 3, respectively. Rod-associated biofilm at timepoint Y (day 35) was sampled and analysed 1 day after dosing cessation. Clindamycin activity was not detected within rod-associated biofilm structures. Vancomycin activity was detected within the planktonic fluid throughout period E and continued to be detected for Crowther et al. 
Discussion
Recurrence of symptoms is a disruptive and costly feature of CDI. 22, 23 Biofilm communities are known to play a role within chronic infection, such as chronic otitis media and periodontitis, and we therefore hypothesized that biofilm structures within the gut could play a role in the recurrence of CDI. We have recently validated the chemostat gut model to facilitate the formation and analysis of mature, mixed-species intestinal biofilms. 16 Using our original CDI gut model, we have previously simulated recurrent infection after initial successful vancomycin treatment, 24, 25 but did so without specific measurement and study of the planktonic versus sessile modes of growth. The modified biofilm gut model has now been utilized to investigate the behaviour of C. difficile and the indigenous gut microbiota in these distinct modes of growth during CDI.
In the absence of antimicrobial intervention (period B), sessile and planktonic gut microbiota and C. difficile behaved in a similar manner. Planktonic populations of obligate anaerobe species were marginally greater than sessile populations, with the converse true for facultative anaerobe populations. A similar trend was previously observed during biofilm model validation studies. 16 Increased sessile compared with planktonic facultative anaerobe populations have been previously observed both in vivo and in vitro. 26, 27 Whilst there are consistencies here, we cannot rule out the possibility that the observation may be (in part) mediated by experimental methods, i.e. increased aerobic handling time required to process biofilm samples. In addition, it should be noted that in order to compare planktonic and biofilm populations, the weight of the pellet from a 1 mL suspension of planktonic culture fluid or resuspended biofilm was used to determine the cfu per gram of biomass. Planktonic cultures are likely to contain a high proportion of bacteria within this biomass whilst biofilm comprises extracellular material in addition to the bacterial mass. Comparison of planktonic and biofilm communities within a gut model 2143 
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The effects of clindamycin instillation on planktonic gut microbiota populations within the model were similar to those observed previously within the original gut model, 28 with a notable deleterious effect on Bifidobacterium spp. and more modest declines in B. fragilis group and Clostridium spp. Similar declines in these groups were also evident in sessile communities. However, although planktonic Bifidobacterium spp. were below the LOD at timepoint Y, sessile communities, whilst reduced from 8.6 log cfu/g, were still detected at 3.9 log 10 cfu/g. At biofilm sampling point Y (period D), planktonic B. fragilis group and Clostridium spp. had recovered to pre-clindamycin levels. However, sessile populations of these groups remained at decreased levels relative to pre-dosing populations. The reduced susceptibility of biofilms to antimicrobial agents is a well-defined characteristic of sessile communities. 29 To date, little work exists investigating the exposure of mixed-species intestinal biofilms to antimicrobial agents, with the majority of groups focusing on simple single-species biofilms. Here, we present evidence of the differences in behaviour of sessile and planktonic gut microbiota populations in response to antimicrobial exposure within mixed-species biofilms. We postulate that clindamycin elicits an antimicrobial effect on both communities, although the effects of and recovery from antimicrobial exposure for sessile populations appears to be delayed compared with responses for planktonic bacteria. Clindamycin was used to induce C. difficile germination, proliferation and toxin production. Simulated planktonic CDI was evident 5 days after cessation of clindamycin dosing, whilst gut microbiota remained perturbed. Clindamycin demonstrates an in vitro activity against vegetative C. difficile (PCR ribotype 027 planktonic MIC of 1 mg/L), potentially preventing germination until only sub-MIC levels remained within the system. This was achieved 4 days after dosing cessation within vessel 3.
The behaviour of C. difficile within planktonic communities was as previously observed. 28, 30 However, distinct differences between the planktonic and biofilm modes of growth were evident, with biofilm-associated C. difficile communities remaining in spore form for the duration of the experiment, despite germination and proliferation of planktonic C. difficile populations. Mechanisms and conditions necessary to induce CDI remain to be fully elucidated. CDI is frequently associated with the use of antimicrobial agents, leading to the assumption that the disruption of the gut microbiota may play a role in the pathogenesis of C. difficile. Clindamycininduced perturbation of planktonic gut microbiota is evident within the gut model. Instillation of spores concurrent with administration of clindamycin consistently leads to CDI within the gut model, whilst this is not the case in the absence of antimicrobial administration. This gut microbiota disruption was also evident within sessile communities but did not elicit germination and proliferation of sessile C. difficile. On day 35 (sample point Y), clindamycin was detected within planktonic fluid at a level of 50.8 mg/L, but no antibiotic activity was detected within biofilm structures. Despite the absence of detectable clindamycin within biofilm, antimicrobial disruption of sessile communities was observed. However, it should be noted that the protocol used to resuspend rod-associated biofilm in this study included multiple centrifugation and vortexing steps. As a result, only toxin and antimicrobial agents securely bound to biofilm structures will be detected using the cytotoxin assay and antimicrobial bioassay.
Studies on exposure of Staphylococcus aureus 31 and Propionibacterium acnes 32 biofilms to clindamycin highlight the differences in planktonic MIC/sessile MBC values (0.25/.128 and 0.125/512 mg/L, respectively), indicating the reduced susceptibility of sessile versus planktonic bacteria to antimicrobials. Another study reported that 20% -99% (mean 62%) of S. aureus biofilm-associated cells survived after clindamycin exposure. 33 This highlights the complex and variable nature of the biofilm mode of growth. Heterogeneity in metabolic and reproductive activity exists amongst cells located in different parts of biofilm. We clearly observed a differential response of sessile bacteria to antimicrobial administration, with C. difficile spores being largely unresponsive either to clindamycin instillation or perturbation of gut microbiota.
Dawson et al. 13 demonstrated that 6-day-old biofilms contained greater numbers of spores compared with 3-day-old biofilms, thus providing evidence of heterogenetic C. difficile composition in distinct biofilm lifecycle stages. In addition, Ethapa et al. 15 demonstrated that C. difficile Spo0A mutants were defective for biofilm formation, demonstrating a possible link between biofilm formation and sporulation in C. difficile. Similar observations in other sporeforming sessile bacteria have been noted. 34 -36 However, Ethapa et al. 15 demonstrated extremely low numbers of spores in biofilm and planktonic phases. It is possible that germinants required for efficient germination may be prevented from accessing the spores within biofilms. In addition to the putative role of Spo0A in biofilm formation, Deakin et al. 37 have demonstrated that Spo0A is required for recurrence of CDI within a murine model. Whilst the majority of spores within a planktonic population initiate rapid germination in response to germinants, a subpopulation of spores is refractory to these stimuli and the germination process is slow. This response is termed 'superdormancy' and has been most extensively characterized in Bacillus spp. 38 -40 The persistence of a superdormant fraction of C. difficile spores after exposure to germinants has been described, 41 although understanding in this area remains basic. Sessile spores may display analogies to superdormant spores and display increased recalcitrance to germination, resulting in high spore populations.
Following planktonic C. difficile germination, proliferation and toxin production, planktonic Bifidobacterium spp. populations began to recover to pre-clindamycin levels, although this was at a greater rate than sessile recovery, providing further evidence for the delayed reaction of sessile versus planktonic communities. The increase in biofilm populations is likely mediated predominantly by recruitment of planktonic cells rather than the active proliferation of sessile populations, due to the inherent dormant, slow-growing nature of the latter communities. Recruitment of planktonic cells requires the planktonic population to increase in number to facilitate transfer to the biofilm mode of growth, possibly explaining the delayed recovery of sessile compared with planktonic communities.
Planktonic C. difficile viable counts declined rapidly and reconverged with spore counts 2 days after exposure to vancomycin. Cytotoxin was reduced to undetectable levels 5 days after vancomycin commencement. Sessile C. difficile, which remained as spores, were not affected by vancomycin instillation, potentially due to the absence of antispore activity of vancomycin. Vancomycin instillation elicited a marked deleterious effect on planktonic B. fragilis group and Bifidobacterium spp. and increase in Lactobacillus spp., as previously observed within the gut model. 28, 30 Similar declines and increases in sessile communities were also observed during period W (and period V), demonstrating
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the proficient effect of vancomycin on sessile populations. Delay in the response of sessile communities to vancomycin instillation was not evident at timepoint W, despite a post-clindamycin delay observed at timepoint Y. This may be due to different antimicrobial agents eliciting different responses in sessile communities or due to differential timing of sampling. Timepoint W was 3 days after cessation of vancomycin, whereas timepoint Y was only 1 day after clindamycin cessation. It is possible that a delay in the response of sessile communities to vancomycin may still occur pre-timepoint W, but may no longer be apparent by the time rods were sampled. Additionally, it has been reported that vancomycin displays a more profound action against sessile communities compared with clindamycin. 33 Vancomycin activity within the rod-associated biofilm structures at timepoint W averaged 40 mg/L, demonstrating the successful diffusion of this agent into biofilm structures. This level is similar to the in vitro MIC (16 -32 mg/L) of vancomycin for B. fragilis. Increased vancomycin concentration within biofilms versus the planktonic phase, as observed within this study, has previously been reported. 42 One study reported that exposure of sessile Staphylococcus epidermidis to increasing concentrations of vancomycin elicited greater antibiotic levels within biofilms. 43 Vancomycin treatment of simulated CDI was initially successful, but planktonic C. difficile populations remained as spores after cessation of antibiotic instillation. Recurrence of CDI was evident 18 days after vancomycin cessation, with an increase in C. difficile viable counts and toxin. Sessile C. difficile populations remained in spore form throughout. Population levels were maintained at 5 log 10 cfu/g from timepoint Z through to U, despite fluctuations in planktonic populations, demonstrating the highly stable nature of sessile C. difficile populations. Early signs of CDI recurrence were evident on day 67 (18 days after vancomycin instillation ceased). However, at this point most gut microbiota populations had recovered to pre-dosing levels. Bifidobacterium spp. levels began to recover, reaching populations of 6.5 log 10 cfu/g on day 67. Despite recovery of gut microbiota, subsequent CDI recurrence was evident, suggesting recurrence is a complex process not only reliant on gut microbiota-associated 'colonization resistance'.
Biofilm dispersal mechanisms are important factors for microbial survival, allowing single organisms or biofilm aggregates to colonize new niches. Many factors are thought to mediate this dispersal, including regulatory systems (e.g. quorum sensing), 44 active dispersal mechanisms (e.g. matrix-degrading enzymes) 45 and changes in nutrient levels. 46 Various dispersal mechanisms are in continued operation within the biofilm lifecycle. The persistence of a stable population of C. difficile spores within biofilms was observed in this study. Within Bacillus subtilis, gene expression is described as a dynamic process during biofilm development. Cells expressing certain genes localized at distinct regions of a biofilm, with spores located on the outer edge of biofilm structures. This provides an ideal nidus for B. subtilis spores and their seeding into the surrounding environment. B. subtilis and C. difficile sporulation (and potentially biofilm formation) are regulated by Spo0A, for which they share 56% amino acid homology. C. difficile may potentially display similar cellular expression pathways and spatial biofilm architecture to B. subtilis, thereby providing a mechanism for reseeding of C. difficile spores into the planktonic form.
The maintenance of a dormant C. difficile spore state within the modified biofilm model, but presence of low levels of biofilm-associated toxin and high levels of planktonic toxin, indicates the diffusion of planktonic-associated toxin into the biofilm. Mucosal biofilms potentially cover toxin receptors; therefore, the presence of toxin within these structures may be required to localize toxin in close proximity to receptors. However, the persistence of biofilm-associated toxin was not prolonged and detected only at low levels, suggesting a minimal impact on contribution to disease. The presence of pseudomembranous legions on the mucosal surface in vivo is evidence that the action of toxin occurs at this site. It is possible that disruption of the mucosal biofilm, possibly by antimicrobial therapy, allows access of toxins to the mucosal epithelia and their receptors. Alternatively, extensive mucosal biofilms in vivo may facilitate the sequestration of toxin at concentrations greater than those observed in this study.
We have demonstrated clear differences between planktonic versus biofilm-associated C. difficile populations. The factors responsible for these differences remain to be fully elucidated. This project has identified the potential role of biofilms in the recurrence of CDI, which is a major clinical challenge. 2 A better understanding of the role of biofilm structures in CDI and recurrent infection could facilitate novel treatment regimens or agents that have improved efficacy against sessile and planktonic communities.
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